Articles tagged with Chemotherapy
Researchers create micro-sized gas bubbles coated with cancer drug particles that can be directed to a specific tumour using magnets and ultrasound. This innovative technique aims to overcome limitations of chemotherapy by delivering drugs directly to the core of the tumour.
Researchers at Beth Israel Deaconess Medical Center have found a way to attack a process that tumor cells use to escape the effects of standard cancer drugs. The discovery highlights how targeting specific metabolic requirements of cancer cells can prove effective in their selective eradication.
Patients with EGFR expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy. The addition of necitumumab improves overall survival and progression-free survival by 21% and 16%, respectively, in patients whose tumours express the EGFR protein.
A phase Ib trial demonstrated that combining immunotherapy with live bacterium CRS-207 and chemotherapy resulted in a 94% disease control rate and 59% response rate in patients with malignant pleural mesothelioma. The therapy also showed good immune activation and synergistic efficacy with chemotherapy.
Researchers at the University of Missouri have discovered a compound that not only lowers cholesterol but also kills prostate cancer cells. The study found that the compound, initially developed as a cholesterol-fighting molecule, reduced prostate cancer cell growth and caused cancer cell death in human and mouse models.
Researchers at Children's Hospital Los Angeles found that targeting survivin enhances chemotherapy effectiveness in retinoblastoma cells and mouse models. The combination of a survivin inhibitor with chemotherapy agents increased Rb cell death, demonstrating a therapeutic advantage.
Patients with grade 2 gliomas treated with radiation therapy plus chemotherapy had a better overall survival of 13.3 years compared to 7.8 years without chemotherapy. The study also found that patients with IDH1 mutation had significantly better overall survival regardless of treatment.
Researchers have developed an implantable device that delivers chemotherapy drugs directly to pancreatic tumors, showing promising results in slowing disease progression and shrinking tumors. The device uses a flexible film that conforms to the tumor shape and releases drugs locally, minimizing side effects and improving treatment outc...
A new hybrid drug combines parts of chloroquine and a chemoreversal agent to counteract malaria resistance. The dual-acting mechanism kills the parasite by concentrating the drug in its stomach.
Researchers at CNIO have identified a protein, CDC25A, as a determinant of chemotherapy resistance in cancer cells. They used CRISPR genome editing technology to test various mutations and found that cells with this mutation were resistant to treatment.
Patients with grade 2 glioma who received radiation therapy plus PCV chemotherapy experienced longer progression-free and overall survival times compared to those who received radiation therapy alone. The treatment combination improved survival rates by up to 10 years.
A phase 1b clinical trial shows that an experimental therapy can control pancreatic cancer tumors well enough to make patients eligible for surgery. The treatment, PF-04136309, was found to be safe and effective when combined with chemotherapy.
A new study reveals that despite the availability of lung cancer tests and treatment to 70% of the world's population, large discrepancies exist in patient access. The study found that many poorer countries lack access to essential tests and treatments due to high costs and low HDI scores.
Researchers have discovered that high doses of cyclophosphamide can selectively kill reactive immune cells, reducing the severity of graft-versus-host disease (GVHD) in patients. This breakthrough has paved the way for the use of mismatched donors in stem cell transplantation, improving access to treatment for many patients.
Scientists developed triple-stage nanoparticles that improve tumor penetration and release cisplatin in acidic conditions, enhancing its efficacy while reducing toxic side effects. The delivery system demonstrated significant improvements in anti-tumor activity against various cancer models.
Researchers developed a new technique using nanoparticles that deliver therapeutic payloads and glow green when cancer cells begin dying. This allows for early detection of treatment effectiveness, potentially improving patient outcomes and quality of life.
A study published in Antimicrobial Agents and Chemotherapy found that patients with S. aureus skin and soft tissue infections took only 57% of their prescribed antibiotic doses after leaving the hospital. This led to nearly half of them getting a new infection or requiring additional treatment.
A study published in The Lancet Oncology found that most female childhood cancer survivors can conceive, but male survivors are less likely to father a child due to chemotherapy exposure. Female survivors treated with certain drugs like ifosfamide and cisplatin may face challenges conceiving, particularly after age 30.
Researchers at Queensland University of Technology have developed a new 3D printable material that mimics human tissue, allowing for the creation of tumor microenvironments to test anti-cancer drugs. This breakthrough enables rapid, personalized cancer treatment targeting tumors, not entire bodies.
African American patients are less likely to receive a common genomic test that predicts the seriousness of early-stage breast cancer. The study found higher scores among African Americans, indicating an increased likelihood of aggressive tumor biology benefiting from chemotherapy.
Researchers have synthesized novel selenohydantoins with promising anticancer and antioxidant activity, leveraging the potential of selenium to slow down oxidation processes. The study's findings highlight the importance of structural modification in influencing biological activity.
A new study from the University of Texas M. D. Anderson Cancer Center found that neurofeedback significantly reduces chronic pain and improves quality of life in cancer patients with chemotherapy-induced neuropathy. The treatment, which uses electroencephalogram biofeedback to modify brain activity, showed a 73% improvement rate in pai...
A new study found that a 21-gene test can identify patients with early breast cancer who can be spared chemotherapy and still survive five years after diagnosis. The trial showed a 94% disease-free survival rate among low-risk patients treated with hormone therapy alone.
A new study found that low expression of SMARCA4/BRG1 gene in lung tumors may indicate patients who will benefit from certain chemotherapy regimens. The findings suggest an alternative therapy for these patients to spare them from cisplatin's side effects and allow them to try a different treatment sooner.
Researchers at Rice University have developed a new method for synthesizing the potent anti-cancer agent trioxacarcin, which damages DNA and disrupts cancer cell replication. This breakthrough allows for more efficient production of these valuable molecules, enabling their study as potential new medications.
A clinical trial found that approximately a quarter of women with HER2 positive breast cancer who received combination treatment experienced significant tumor shrinkage or disappearance within 11 days. This discovery offers the possibility of tailoring treatment for each woman, potentially reducing the need for chemotherapy.
Researchers found that dose-dense adjuvant chemotherapy significantly improved overall survival after ten years by nearly a third compared to standard interval regimens. Dose-dense chemotherapy was not associated with an increased risk of treatment-induced amenorrhea, and it seemed effective irrespective of hormone receptor status.
Researchers identified 12 classes of drugs and 4 main mechanisms that can cause small arteries to constrict in response to cold, limiting blood supply. A recent study published in British Journal of Clinical Pharmacology highlights the need for further investigation into this condition.
Nanoparticulate drug carriers show promise in targeted cancer therapy, increasing therapeutic concentrations at tumor sites while minimizing harm to healthy tissues. This approach has the potential to improve treatment efficacy and reduce systemic toxicity.
Researchers at St. Joseph's Hospital and Medical Center found that a standard front-line treatment for advanced ovarian cancer should involve every three week chemotherapy with carboplatin, paclitaxel plus bevacizumab, or weekly dose intense paclitaxel without bevacizumab
Researchers develop adaptive therapy that adjusts drug dose based on tumor response, controlling growth and allowing 60-80% of mice to be weaned off the drug. The treatment approach stabilizes tumors by maintaining a small population of drug-sensitive cells to suppress resistant cell growth.
Researchers have found that laser ablation creates a temporary opening in the blood-brain barrier, allowing chemotherapy drugs to pass into the brain. This breakthrough raises hopes for longer treatment options and improved patient outcomes.
Using laser probe, neurosurgeons deliver chemotherapy drugs to patients with glioblastoma after opening the blood-brain barrier. The technology allows for longer treatment windows and potentially limits harmful effects of chemotherapy.
Researchers at MDI Biological Laboratory have discovered two drugs that could reverse peripheral nerve damage caused by chemotherapy, with applications also for diabetes and traumatic injuries. The drugs reduce MMP-13 activity, preventing degeneration of axons and restoring touch response in zebrafish.
A large-scale analysis of patient records found that chemotherapy before radiation therapy did not improve overall survival rates for head and neck cancer patients. Patients who received concurrent chemotherapy and radiation had slightly longer median overall survival times compared to those receiving chemotherapy alone.
Researchers from Case Western Reserve University have developed a new image analytics test that can reliably distinguish between patients who need only hormonal treatment and those who also need chemotherapy. The test uses MRI data to identify molecular changes in tissues, which can be analyzed quickly and cost-effectively.
A new study suggests that patients with resectable pancreatic cancer should receive at least 6 months of adjuvant chemotherapy to reduce distant disease recurrences and improve overall survival. Chemotherapy, but not chemoradiotherapy, significantly reduces the incidence of distant recurrence.
A recent clinical study found that ONC201 caused cell death in various tumor types, even when the p53 protein was mutated or deleted. The drug has shown promise in treating hematological malignancies, including leukemia and lymphoma patients, with clinical trials recently initiated.
Researchers from Massachusetts General Hospital report that inducing cytotoxic T cell infiltration into lung tumors can make them sensitive to checkpoint blockade. Combining chemotherapy with immune checkpoint therapies achieves long-lasting control of tumor growth in animal models, expanding the potential for effective treatment.
Researchers found that pediatric ALL patients treated with chemotherapy alone remain at risk for attention and learning problems, even after treatment ends. The study, published in the Journal of Clinical Oncology, suggests that early intervention is crucial to prevent academic difficulties.
A new study from Children's Hospital Los Angeles found that leukemia therapy leads to a significant drop in bone mineral density during the first month of treatment, affecting the lower spine and legs. This earlier onset than previously thought highlights the need for new approaches to mitigate bone toxicity in cancer patients.
Researchers at Rockefeller University have captured atomic images of the herpes simplex 1 virus revealing how it inserts itself into another protein to evade detection by immune cells. The study provides a mechanistic explanation for the virus's ability to escape immune system recognition.
A portable method to detect tainted medicines and supplements has been developed by a CWRU researcher, potentially improving public health globally. The device uses Nuclear Quadrupole Resonance spectroscopy to authenticate good medicines and supplements, while also addressing the issue of counterfeit products.
A study by University of Minnesota researchers identified the mechanism of 5-azacytidine, a DNA-based drug that blocks HIV's ability to spread. The drug converts to a DNA form and infiltrates HIV when it turns RNA into DNA, stopping replication.
Experts have issued a framework to guide difficult prioritization decisions among children in need of scarce life-saving chemotherapy treatment. The modified utilitarian model maximizes total benefit from available supply, considering factors like curability, prognosis, and drug importance.
Microtubules can spontaneously form large networks through the interaction of motor proteins. This self-organization is crucial for cell division and may inspire new materials and drug designs. Researchers developed a model describing this behavior, which could lead to breakthroughs in biology and material science.
A three-year study funded by PCORI investigates the safety and patient preferences of discharge strategies after chemotherapy for children with acute myeloid leukemia. The study aims to gather data on bloodstream infections and chemotherapy delays to inform better care for these vulnerable patients.
Chemotherapy can reduce the body's immune response, leaving breast cancer survivors vulnerable to illnesses. Researchers found that levels of lymphocytes and antibodies dropped significantly after chemotherapy, with only partial recovery in some cases.
A new treatment model recommends aggressive surgery followed by targeted chemotherapy to achieve a 50% cure rate for women with advanced-stage ovarian cancer. This approach differs from current conventional treatments, which often result in a 20% survival rate.
A new biomarker, CDX2, has been identified that predicts which stage II colon cancer patients may benefit from chemotherapy. The study found that tumors lacking CDX2 expression were more likely to benefit from adjuvant chemotherapy than those with CDX2 expression.
Researchers have identified a biomarker, CDX2, that can predict which Stage II colon cancer patients are most likely to benefit from chemotherapy after surgery. The study found that patients without CDX2 had poorer outcomes, but those treated with chemotherapy had improved survival rates.
Researchers have discovered a way to light up a common cancer drug, allowing them to see where the chemo goes and how long it takes to get there. This breakthrough could lead to more personalized medicine and better understanding of how cells interact with drugs.
Researchers from the Repurposing Drugs in Oncology project have found that diclofenac, a common painkiller, has significant anti-cancer properties. The study suggests that existing non-cancer drugs may represent a valuable source of novel therapies for cancer treatment.
Scientists have developed a new strategy for constructing highly specific synthetic pores using DNA, which can control the release of therapeutics. The pores are designed to act like doors, opening only when provided with the right key, allowing for precise targeting of drugs to specific tissues.
Researchers developed a device that produces tiny capsules with multiple inner ingredients, which can be triggered to mix and release toxic product only near the tumor site. The method has shown promise for increasing drug efficiency while reducing side effects in cancer treatment.
A new study reveals that docetaxel retains effectiveness in patients with castration-resistant metastatic prostate cancer (mCRPC) treated with abiraterone. Following abiraterone, 40% of patients experienced a 50% reduction in prostate-specific antigen (PSA), demonstrating the activity of this drug sequencing.
A study by CNIC researchers has identified a new mechanism through which blood stem cells regulate their proliferation and microenvironment. The protein ESL-1 controls the production of TGF-, a cytokine with antiproliferative properties, and is essential for maintaining HSCs in diseases like anemia.
Researchers from Colorado State University have discovered that RNA plays a crucial role in DNA damage, leading to mutations and disease. The study sheds light on the mechanisms behind Aicardi-Goutieres syndrome and has implications for cancer research.
A study found that women with breast cancer who received chemotherapy and triptorelin had a higher long-term probability of ovarian function recovery without affecting pregnancy rates or disease-free survival. The treatment showed modest benefits regarding potential prevention of treatment-associated infertility.
Researchers have developed models to rationalize the action of chemotherapeutic molecules on body cells, enabling better understanding of how drugs interact with biological targets. The study aims to improve the design of new therapeutic molecules, resulting in more effective and side-effect-free drugs.